SG182417A1 - 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases - Google Patents
5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases Download PDFInfo
- Publication number
- SG182417A1 SG182417A1 SG2012050241A SG2012050241A SG182417A1 SG 182417 A1 SG182417 A1 SG 182417A1 SG 2012050241 A SG2012050241 A SG 2012050241A SG 2012050241 A SG2012050241 A SG 2012050241A SG 182417 A1 SG182417 A1 SG 182417A1
- Authority
- SG
- Singapore
- Prior art keywords
- amino
- carboxamide
- dihydropyrido
- pyrimidine
- oxo
- Prior art date
Links
- BYTRPZLYYIPRLJ-UHFFFAOYSA-N 8h-pyrido[2,3-d]pyrimidin-5-one Chemical class C1=NC=C2C(O)=CC=NC2=N1 BYTRPZLYYIPRLJ-UHFFFAOYSA-N 0.000 title abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 title description 2
- 229940043355 kinase inhibitor Drugs 0.000 title description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 2
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 claims description 192
- 150000001875 compounds Chemical class 0.000 claims description 97
- 125000005843 halogen group Chemical group 0.000 claims description 81
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 74
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 57
- 125000001424 substituent group Chemical group 0.000 claims description 55
- 229920006395 saturated elastomer Polymers 0.000 claims description 46
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 38
- 239000002253 acid Substances 0.000 claims description 30
- -1 1,1-dioxo-1lambda6-thiomorpholin-4-yl Chemical group 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 claims description 22
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000004429 atom Chemical group 0.000 claims description 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 230000007170 pathology Effects 0.000 claims description 13
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
- 229910052770 Uranium Inorganic materials 0.000 claims description 8
- 125000005936 piperidyl group Chemical group 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 206010016654 Fibrosis Diseases 0.000 claims description 7
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 7
- 230000004761 fibrosis Effects 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 150000003951 lactams Chemical class 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 4
- 208000033626 Renal failure acute Diseases 0.000 claims description 4
- 206010003119 arrhythmia Diseases 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 150000003141 primary amines Chemical class 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 claims description 2
- MFROERBVDHRYCD-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-7-amino-8-ethyl-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 MFROERBVDHRYCD-UHFFFAOYSA-N 0.000 claims description 2
- UFIACMRECAQGAC-UHFFFAOYSA-N 7-amino-2-(4-cyclopentyloxyanilino)-8-ethyl-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1OC1CCCC1 UFIACMRECAQGAC-UHFFFAOYSA-N 0.000 claims description 2
- APHXMUGLFWSRQV-UHFFFAOYSA-N 7-amino-8-(2-aminoethyl)-2-(4-morpholin-4-ylanilino)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CCN)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 APHXMUGLFWSRQV-UHFFFAOYSA-N 0.000 claims description 2
- WMAMDNOLXLSQKB-UHFFFAOYSA-N 7-amino-8-(3-methoxypropyl)-2-[4-(2-morpholin-4-ylethyl)anilino]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CCCOC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1CCN1CCOCC1 WMAMDNOLXLSQKB-UHFFFAOYSA-N 0.000 claims description 2
- XNLPBAPZJYSBES-UHFFFAOYSA-N 7-amino-8-ethyl-2-(4-morpholin-4-ylanilino)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 XNLPBAPZJYSBES-UHFFFAOYSA-N 0.000 claims description 2
- CYLAUECOYULTHH-UHFFFAOYSA-N 7-amino-8-ethyl-2-[4-(1-ethylpiperidin-4-yl)anilino]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound C1CN(CC)CCC1C(C=C1)=CC=C1NC1=NC=C2C(=O)C(C(N)=O)=C(N)N(CC)C2=N1 CYLAUECOYULTHH-UHFFFAOYSA-N 0.000 claims description 2
- WFJNNWBNWZAZPP-UHFFFAOYSA-N 7-amino-8-ethyl-5-oxo-2-(4-pyrrolidin-3-ylanilino)pyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1C1CCNC1 WFJNNWBNWZAZPP-UHFFFAOYSA-N 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 125000005959 diazepanyl group Chemical group 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 2
- MRMSMUZFQQEEMP-UHFFFAOYSA-N 2-[7-amino-8-ethyl-2-[2-methoxy-4-(4-morpholin-4-ylpiperidin-1-yl)anilino]-5-oxopyrido[2,3-d]pyrimidin-6-yl]acetamide Chemical compound NC1=C(C(C2=C(N=C(N=C2)NC2=C(C=C(C=C2)N2CCC(CC2)N2CCOCC2)OC)N1CC)=O)CC(=O)N MRMSMUZFQQEEMP-UHFFFAOYSA-N 0.000 claims 1
- MFVOPMWMUPXBPY-UHFFFAOYSA-N 7-amino-2-(2-methoxy-4-morpholin-4-ylanilino)-5-oxo-8-(pyrrolidin-3-ylmethyl)pyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(C(C(C(N)=O)=C2N)=O)C=1N2CC1CCNC1 MFVOPMWMUPXBPY-UHFFFAOYSA-N 0.000 claims 1
- WCQRQFMYDFAFBY-UHFFFAOYSA-N 7-amino-2-[2-methoxy-4-(2-pyrrolidin-1-ylethyl)anilino]-5-oxo-8-phenylpyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound C=1C=C(NC=2N=C3C(C(C(C(N)=O)=C(N)N3C=3C=CC=CC=3)=O)=CN=2)C(OC)=CC=1CCN1CCCC1 WCQRQFMYDFAFBY-UHFFFAOYSA-N 0.000 claims 1
- DXHKCCUMIZFGOJ-UHFFFAOYSA-N 7-amino-2-[3-[(dimethylamino)methyl]anilino]-8-ethyl-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC1=CC=CC(CN(C)C)=C1 DXHKCCUMIZFGOJ-UHFFFAOYSA-N 0.000 claims 1
- ZRQLWBZFRLHXBV-UHFFFAOYSA-N 7-amino-2-[3-chloro-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]-8-ethyl-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1Cl)=CC=C1N(CC1)CCC1N1CCCC1 ZRQLWBZFRLHXBV-UHFFFAOYSA-N 0.000 claims 1
- VDJUKCSRVPWHMA-UHFFFAOYSA-N 7-amino-2-[4-(4-cyclopropylpiperazin-1-yl)-2-(difluoromethoxy)anilino]-8-ethyl-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C(=C1)OC(F)F)=CC=C1N(CC1)CCN1C1CC1 VDJUKCSRVPWHMA-UHFFFAOYSA-N 0.000 claims 1
- JJYGSJJVOICYHO-UHFFFAOYSA-N 7-amino-2-[4-(4-cyclopropylpiperazin-1-yl)anilino]-8-ethyl-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1N(CC1)CCN1C1CC1 JJYGSJJVOICYHO-UHFFFAOYSA-N 0.000 claims 1
- BHBAMVLIFUDMOO-UHFFFAOYSA-N 7-amino-2-[4-[(dimethylamino)methyl]anilino]-5-oxo-8-(2,2,2-trifluoroethyl)pyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound C1=CC(CN(C)C)=CC=C1NC1=NC=C2C(=O)C(C(N)=O)=C(N)N(CC(F)(F)F)C2=N1 BHBAMVLIFUDMOO-UHFFFAOYSA-N 0.000 claims 1
- JIHHEGFWYHPYBB-UHFFFAOYSA-N 7-amino-2-[4-[(dimethylamino)methyl]anilino]-5-oxo-8-propan-2-ylpyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C(C)C)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC1=CC=C(CN(C)C)C=C1 JIHHEGFWYHPYBB-UHFFFAOYSA-N 0.000 claims 1
- UEIKVFSKXSDJCI-UHFFFAOYSA-N 7-amino-2-[4-[(dimethylamino)methyl]anilino]-8-(3-methoxypropyl)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CCCOC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC1=CC=C(CN(C)C)C=C1 UEIKVFSKXSDJCI-UHFFFAOYSA-N 0.000 claims 1
- ONVWRBADCQPZMO-UHFFFAOYSA-N 7-amino-2-[4-[(dimethylamino)methyl]anilino]-8-ethyl-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC1=CC=C(CN(C)C)C=C1 ONVWRBADCQPZMO-UHFFFAOYSA-N 0.000 claims 1
- MCQZANXRAZLAAW-UHFFFAOYSA-N 7-amino-2-[4-[1-(2-cyanoethyl)piperidin-4-yl]anilino]-8-ethyl-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1C1CCN(CCC#N)CC1 MCQZANXRAZLAAW-UHFFFAOYSA-N 0.000 claims 1
- MBPJFGITLUGESK-UHFFFAOYSA-N 7-amino-8-(2-methylpropyl)-2-[4-(2-morpholin-4-ylethyl)anilino]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC(C)C)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1CCN1CCOCC1 MBPJFGITLUGESK-UHFFFAOYSA-N 0.000 claims 1
- KAFVSDZAEDMXMK-UHFFFAOYSA-N 7-amino-8-(3-aminopropyl)-2-(4-morpholin-4-ylanilino)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CCCN)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 KAFVSDZAEDMXMK-UHFFFAOYSA-N 0.000 claims 1
- KBJJIQLSVFNGNP-UHFFFAOYSA-N 7-amino-8-ethyl-2-(3-fluoro-4-hydroxyanilino)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC1=CC=C(O)C(F)=C1 KBJJIQLSVFNGNP-UHFFFAOYSA-N 0.000 claims 1
- CAQYZKAYWIARHL-UHFFFAOYSA-N 7-amino-8-ethyl-2-(3-methylsulfanylanilino)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC1=CC=CC(SC)=C1 CAQYZKAYWIARHL-UHFFFAOYSA-N 0.000 claims 1
- FJXCWEUDRARBQM-UHFFFAOYSA-N 7-amino-8-ethyl-2-[4-(2-morpholin-4-ylethoxy)anilino]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1OCCN1CCOCC1 FJXCWEUDRARBQM-UHFFFAOYSA-N 0.000 claims 1
- YSJAJJXVBORMII-UHFFFAOYSA-N 7-amino-8-ethyl-2-[4-(4-ethyl-1,4-diazepan-1-yl)anilino]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound C1CN(CC)CCCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)C(C(N)=O)=C(N)N(CC)C2=N1 YSJAJJXVBORMII-UHFFFAOYSA-N 0.000 claims 1
- FGEYBTGHYRTKLL-UHFFFAOYSA-N 7-amino-8-ethyl-2-[4-(4-ethylpiperazin-1-yl)-3-methylanilino]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound C1CN(CC)CCN1C(C(=C1)C)=CC=C1NC1=NC=C2C(=O)C(C(N)=O)=C(N)N(CC)C2=N1 FGEYBTGHYRTKLL-UHFFFAOYSA-N 0.000 claims 1
- VYBUROBXHODJAF-UHFFFAOYSA-N 7-amino-8-ethyl-2-[4-(morpholin-4-ylmethyl)anilino]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1CN1CCOCC1 VYBUROBXHODJAF-UHFFFAOYSA-N 0.000 claims 1
- RBEAANSDVZZGSR-UHFFFAOYSA-N 7-amino-8-ethyl-5-oxo-2-(4-piperidin-4-ylanilino)pyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1C1CCNCC1 RBEAANSDVZZGSR-UHFFFAOYSA-N 0.000 claims 1
- MOGIICROERPQPE-UHFFFAOYSA-N 7-amino-8-ethyl-5-oxo-2-[4-(3-piperidin-1-ylpropoxy)anilino]pyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1OCCCN1CCCCC1 MOGIICROERPQPE-UHFFFAOYSA-N 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000016273 neuron death Effects 0.000 claims 1
- 230000006439 vascular pathology Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 25
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 173
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 168
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 157
- 239000000203 mixture Substances 0.000 description 156
- 239000007787 solid Substances 0.000 description 116
- 239000000243 solution Substances 0.000 description 100
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 98
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 95
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 69
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 60
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 50
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 48
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 48
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 46
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 44
- 239000012074 organic phase Substances 0.000 description 34
- 239000002244 precipitate Substances 0.000 description 33
- 235000019439 ethyl acetate Nutrition 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 32
- 238000004587 chromatography analysis Methods 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 29
- 239000000725 suspension Substances 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 239000000377 silicon dioxide Substances 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 238000001914 filtration Methods 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 229910000104 sodium hydride Inorganic materials 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000002585 base Substances 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 239000012312 sodium hydride Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000005457 ice water Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 8
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 8
- VMKJWLXVLHBJNK-UHFFFAOYSA-N cyanuric fluoride Chemical compound FC1=NC(F)=NC(F)=N1 VMKJWLXVLHBJNK-UHFFFAOYSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 229940043709 CaM kinase II inhibitor Drugs 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000003365 glass fiber Substances 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 150000003457 sulfones Chemical class 0.000 description 6
- 150000003462 sulfoxides Chemical class 0.000 description 6
- WRSMVHZKPDCKNQ-DBSTUJSUSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]ami Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN WRSMVHZKPDCKNQ-DBSTUJSUSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 239000002798 polar solvent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IVIHUCXXDVVSBH-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)N=C1Cl IVIHUCXXDVVSBH-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 4
- 208000006029 Cardiomegaly Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 108010075874 autocamtide-2 Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- UKHJWFBLUSBUKL-UHFFFAOYSA-N 7-amino-8-ethyl-2-(4-hydroxyanilino)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC1=CC=C(O)C=C1 UKHJWFBLUSBUKL-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100033086 Calcium/calmodulin-dependent protein kinase type 1 Human genes 0.000 description 3
- 102000000584 Calmodulin Human genes 0.000 description 3
- 108010041952 Calmodulin Proteins 0.000 description 3
- 101000944250 Homo sapiens Calcium/calmodulin-dependent protein kinase type 1 Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- LXQMHOKEXZETKB-UHFFFAOYSA-N 1-amino-2-methylpropan-2-ol Chemical compound CC(C)(O)CN LXQMHOKEXZETKB-UHFFFAOYSA-N 0.000 description 2
- DZTIFMWYYHCREC-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carbonyl chloride Chemical compound ClC(=O)C1=CN=C(Cl)N=C1Cl DZTIFMWYYHCREC-UHFFFAOYSA-N 0.000 description 2
- RVCLISIPGZGQPU-UHFFFAOYSA-N 2,6-dichloro-3-chlorosulfonylbenzoic acid Chemical compound OC(=O)C1=C(Cl)C=CC(S(Cl)(=O)=O)=C1Cl RVCLISIPGZGQPU-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- YBUBWYNTBBYCOG-UHFFFAOYSA-N 2-chloro-4-[(2-hydroxy-2-methylpropyl)amino]pyrimidine-5-carboxylic acid Chemical compound CC(C)(O)CNC1=NC(Cl)=NC=C1C(O)=O YBUBWYNTBBYCOG-UHFFFAOYSA-N 0.000 description 2
- UTWUINCSWMKVEY-UHFFFAOYSA-N 4-(ethylamino)-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound CCNC1=NC(SC)=NC=C1C(O)=O UTWUINCSWMKVEY-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- PHNDZBFLOPIMSM-UHFFFAOYSA-N 4-morpholin-4-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCOCC1 PHNDZBFLOPIMSM-UHFFFAOYSA-N 0.000 description 2
- PQLVLGOPDFMGNV-UHFFFAOYSA-N 5-oxo-8h-pyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=CN=CC2=C(O)C(C(=O)N)=CN=C21 PQLVLGOPDFMGNV-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 239000012657 CaMKII inhibitor Substances 0.000 description 2
- 108010070997 CaMKII inhibitor AIP Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- LBZSUTCUDDWYRI-UHFFFAOYSA-N ethyl 4-(ethylamino)-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCNC1=NC(SC)=NC=C1C(=O)OCC LBZSUTCUDDWYRI-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010952 in-situ formation Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- MYTIJGWONQOOLC-HNNXBMFYSA-N n'-[3-[(1s)-1-(3-fluoro-4-phenylphenyl)ethyl]-1,2-oxazol-5-yl]morpholine-4-carboximidamide Chemical compound O1N=C([C@@H](C)C=2C=C(F)C(=CC=2)C=2C=CC=CC=2)C=C1\N=C(/N)N1CCOCC1 MYTIJGWONQOOLC-HNNXBMFYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- BZMMRNKDONDVIB-UHFFFAOYSA-N (1-ethoxycyclopropyl)oxy-trimethylsilane Chemical compound CCOC1(O[Si](C)(C)C)CC1 BZMMRNKDONDVIB-UHFFFAOYSA-N 0.000 description 1
- UMRXCSPRJVBXHH-UHFFFAOYSA-N (4-methylpiperazin-1-yl)(4-nitrophenyl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C([N+]([O-])=O)C=C1 UMRXCSPRJVBXHH-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- PWRFDGYYJWQIAB-UHFFFAOYSA-N 1,3,5-trifluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=C(F)C=C1F PWRFDGYYJWQIAB-UHFFFAOYSA-N 0.000 description 1
- DXEGOHULGVHKCT-UHFFFAOYSA-N 1,5-difluoro-3-methoxy-2-nitrobenzene Chemical compound COC1=CC(F)=CC(F)=C1[N+]([O-])=O DXEGOHULGVHKCT-UHFFFAOYSA-N 0.000 description 1
- FMKCHKDLIBKJKO-UHFFFAOYSA-N 1-(4-aminophenyl)-2-methylcyclopropane-1-carboxamide Chemical compound CC1CC1(C(N)=O)C1=CC=C(N)C=C1 FMKCHKDLIBKJKO-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- FXTOUBWTWSIXOT-UHFFFAOYSA-N 1-[2-(3-methoxy-4-nitrophenyl)ethyl]pyrrolidine Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(CCN2CCCC2)=C1 FXTOUBWTWSIXOT-UHFFFAOYSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- TZTBDDXLEXKVET-UHFFFAOYSA-N 1-ethyl-4-(3-methoxy-4-nitrophenyl)piperazine Chemical compound C1CN(CC)CCN1C1=CC=C([N+]([O-])=O)C(OC)=C1 TZTBDDXLEXKVET-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- YAMGYZKPMODVIX-UHFFFAOYSA-N 2-methoxy-4-(1-methylpiperidin-4-yl)aniline Chemical compound C1=C(N)C(OC)=CC(C2CCN(C)CC2)=C1 YAMGYZKPMODVIX-UHFFFAOYSA-N 0.000 description 1
- WHZFWTQHRPWSSZ-UHFFFAOYSA-N 2-methoxy-4-(2-pyrrolidin-1-ylethyl)aniline Chemical compound C1=C(N)C(OC)=CC(CCN2CCCC2)=C1 WHZFWTQHRPWSSZ-UHFFFAOYSA-N 0.000 description 1
- YSEFYOVWKJXNCH-UHFFFAOYSA-N 2-methoxyacetaldehyde Chemical compound COCC=O YSEFYOVWKJXNCH-UHFFFAOYSA-N 0.000 description 1
- RWJTYJIXRRBROS-UHFFFAOYSA-N 2-methyl-1-(4-nitrophenyl)cyclopropane-1-carboxamide Chemical compound CC1CC1(C(N)=O)C1=CC=C([N+]([O-])=O)C=C1 RWJTYJIXRRBROS-UHFFFAOYSA-N 0.000 description 1
- UTMIEQASUFFADK-UHFFFAOYSA-N 3,3,3-trifluoropropanal Chemical compound FC(F)(F)CC=O UTMIEQASUFFADK-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- NMFCNWAISBIGON-UHFFFAOYSA-N 4-(3-methoxy-4-nitrophenyl)-1,2,3,6-tetrahydropyridine;hydrochloride Chemical compound Cl.C1=C([N+]([O-])=O)C(OC)=CC(C=2CCNCC=2)=C1 NMFCNWAISBIGON-UHFFFAOYSA-N 0.000 description 1
- HMHILCRWXQZODU-UHFFFAOYSA-N 4-(4-ethylpiperazin-1-yl)-2-methoxyaniline Chemical compound C1CN(CC)CCN1C1=CC=C(N)C(OC)=C1 HMHILCRWXQZODU-UHFFFAOYSA-N 0.000 description 1
- 150000005007 4-aminopyrimidines Chemical class 0.000 description 1
- PLUFCCGUABTJMO-UHFFFAOYSA-N 4-anilino-2-methylsulfanylpyrimidine-5-carbonyl fluoride Chemical compound CSC1=NC=C(C(F)=O)C(NC=2C=CC=CC=2)=N1 PLUFCCGUABTJMO-UHFFFAOYSA-N 0.000 description 1
- DOPXFPSWBAHAIR-UHFFFAOYSA-N 4-anilino-2-methylsulfanylpyrimidine-5-carboxylic acid Chemical compound CSC1=NC=C(C(O)=O)C(NC=2C=CC=CC=2)=N1 DOPXFPSWBAHAIR-UHFFFAOYSA-N 0.000 description 1
- VQCWSOYHHXXWSP-UHFFFAOYSA-N 4-bromo-2-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1F VQCWSOYHHXXWSP-UHFFFAOYSA-N 0.000 description 1
- DJKPQYBFSAJUBS-UHFFFAOYSA-N 4-bromo-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(Br)=CC=C1[N+]([O-])=O DJKPQYBFSAJUBS-UHFFFAOYSA-N 0.000 description 1
- IOQXLSFKTQQPAO-UHFFFAOYSA-N 4-ethenyl-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(C=C)=CC=C1[N+]([O-])=O IOQXLSFKTQQPAO-UHFFFAOYSA-N 0.000 description 1
- WLKUSVNHZXUEFO-UHFFFAOYSA-N 4-fluoro-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(F)=CC=C1[N+]([O-])=O WLKUSVNHZXUEFO-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- QQURWFRNETXFTN-UHFFFAOYSA-N 5-fluoro-2-nitrophenol Chemical compound OC1=CC(F)=CC=C1[N+]([O-])=O QQURWFRNETXFTN-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- AZEJLDXMUAKRDC-UHFFFAOYSA-N 7-amino-2-(1,3-benzodioxol-5-ylamino)-8-ethyl-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound C1=C2OCOC2=CC(NC2=NC=C3C(=O)C(C(N)=O)=C(N)N(C3=N2)CC)=C1 AZEJLDXMUAKRDC-UHFFFAOYSA-N 0.000 description 1
- WMZGFAFYMYUVFX-UHFFFAOYSA-N 7-amino-2-(2-methoxy-4-piperidin-4-ylanilino)-5-oxo-8-phenylpyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(C2CCNCC2)=CC=C1NC(N=1)=NC=C(C(C(C(N)=O)=C2N)=O)C=1N2C1=CC=CC=C1 WMZGFAFYMYUVFX-UHFFFAOYSA-N 0.000 description 1
- KVPFGRUHSSARJC-UHFFFAOYSA-N 7-amino-2-(2-methoxy-4-piperidin-4-ylanilino)-8-(3-methylphenyl)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(C2CCNCC2)=CC=C1NC(N=1)=NC=C(C(C(C(N)=O)=C2N)=O)C=1N2C1=CC=CC(C)=C1 KVPFGRUHSSARJC-UHFFFAOYSA-N 0.000 description 1
- CTJDIFBBYKSTHF-UHFFFAOYSA-N 7-amino-2-[2-methoxy-4-(1-methylpiperidin-4-yl)anilino]-5-oxo-8-phenylpyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(C2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(C(C(C(N)=O)=C2N)=O)C=1N2C1=CC=CC=C1 CTJDIFBBYKSTHF-UHFFFAOYSA-N 0.000 description 1
- FKTQSHGTFXWLQN-UHFFFAOYSA-N 7-amino-2-[2-methoxy-4-(1-methylpiperidin-4-yl)anilino]-5-oxo-8-phenylpyrido[2,3-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.COC1=CC(C2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(C(C(C(N)=O)=C2N)=O)C=1N2C1=CC=CC=C1 FKTQSHGTFXWLQN-UHFFFAOYSA-N 0.000 description 1
- WRQPQDPYNIZEND-UHFFFAOYSA-N 7-amino-2-[2-methoxy-4-(2-pyrrolidin-1-ylethyl)anilino]-5-oxo-8-phenylpyrido[2,3-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.C=1C=C(NC=2N=C3C(C(C(C(N)=O)=C(N)N3C=3C=CC=CC=3)=O)=CN=2)C(OC)=CC=1CCN1CCCC1 WRQPQDPYNIZEND-UHFFFAOYSA-N 0.000 description 1
- FRKOXURCLGTSKH-UHFFFAOYSA-N 7-amino-2-[2-methoxy-4-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]anilino]-5-oxo-8-(thiophen-2-ylmethyl)pyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(C2CCN(CCC(F)(F)F)CC2)=CC=C1NC(N=1)=NC=C(C(C(C(N)=O)=C2N)=O)C=1N2CC1=CC=CS1 FRKOXURCLGTSKH-UHFFFAOYSA-N 0.000 description 1
- QNYBIWYJGIZJMD-UHFFFAOYSA-N 7-amino-2-[4-(2-morpholin-4-ylethyl)anilino]-5-oxo-8-propylpyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CCC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1CCN1CCOCC1 QNYBIWYJGIZJMD-UHFFFAOYSA-N 0.000 description 1
- XQWOIYPDYGMSHC-UHFFFAOYSA-N 7-amino-2-[4-(4-cyclopropylpiperazin-1-yl)-2-(difluoromethoxy)anilino]-8-ethyl-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C(=C1)OC(F)F)=CC=C1N(CC1)CCN1C1CC1 XQWOIYPDYGMSHC-UHFFFAOYSA-N 0.000 description 1
- BWDRUHNWRBGLCK-UHFFFAOYSA-N 7-amino-2-[4-(4-ethylpiperazin-1-yl)-2-methoxyanilino]-8-(2-hydroxy-2-methylpropyl)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound C1CN(CC)CCN1C(C=C1OC)=CC=C1NC1=NC=C2C(=O)C(C(N)=O)=C(N)N(CC(C)(C)O)C2=N1 BWDRUHNWRBGLCK-UHFFFAOYSA-N 0.000 description 1
- BSPIVUQOEHDHIJ-UHFFFAOYSA-N 7-amino-2-[4-(4-ethylpiperazin-1-yl)-2-methoxyanilino]-8-(2-hydroxy-2-methylpropyl)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.C1CN(CC)CCN1C(C=C1OC)=CC=C1NC1=NC=C2C(=O)C(C(N)=O)=C(N)N(CC(C)(C)O)C2=N1 BSPIVUQOEHDHIJ-UHFFFAOYSA-N 0.000 description 1
- OBELJSXDFFFIEY-UHFFFAOYSA-N 7-amino-2-[4-[1-(2-chloroethyl)piperidin-4-yl]-2-methoxyanilino]-8-(2-hydroxy-2-methylpropyl)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound C=1C=C(NC=2N=C3C(C(C(C(N)=O)=C(N)N3CC(C)(C)O)=O)=CN=2)C(OC)=CC=1C1CCN(CCCl)CC1 OBELJSXDFFFIEY-UHFFFAOYSA-N 0.000 description 1
- AWEUSIZBUJWGAL-UHFFFAOYSA-N 7-amino-8-(3-aminopropyl)-2-(4-morpholin-4-ylanilino)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.N1=C2N(CCCN)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 AWEUSIZBUJWGAL-UHFFFAOYSA-N 0.000 description 1
- ZTIRUYDPAQCSKG-UHFFFAOYSA-N 7-amino-8-(4-fluorophenyl)-2-(2-methoxy-4-piperidin-4-ylanilino)-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(C2CCNCC2)=CC=C1NC(N=1)=NC=C(C(C(C(N)=O)=C2N)=O)C=1N2C1=CC=C(F)C=C1 ZTIRUYDPAQCSKG-UHFFFAOYSA-N 0.000 description 1
- CJJCGVPTZNWENF-UHFFFAOYSA-N 7-amino-8-ethyl-2-[3-methoxy-4-(3-piperidin-1-ylpropoxy)anilino]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1OC)=CC=C1OCCCN1CCCCC1 CJJCGVPTZNWENF-UHFFFAOYSA-N 0.000 description 1
- PMXIQHHJRINJSR-UHFFFAOYSA-N 7-amino-8-ethyl-2-[4-(2-hydroxyethyl)anilino]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC1=CC=C(CCO)C=C1 PMXIQHHJRINJSR-UHFFFAOYSA-N 0.000 description 1
- LMXCEXZYIUCIPQ-UHFFFAOYSA-N 7-amino-8-ethyl-2-[4-(3-morpholin-4-ylpropyl)anilino]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1CCCN1CCOCC1 LMXCEXZYIUCIPQ-UHFFFAOYSA-N 0.000 description 1
- GWGLYDGXLGQPFE-UHFFFAOYSA-N 7-amino-8-ethyl-2-[4-(4-ethylpiperazin-1-yl)-2-fluoroanilino]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound C1CN(CC)CCN1C(C=C1F)=CC=C1NC1=NC=C2C(=O)C(C(N)=O)=C(N)N(CC)C2=N1 GWGLYDGXLGQPFE-UHFFFAOYSA-N 0.000 description 1
- VZHGRZCGUSGDLH-UHFFFAOYSA-N 7-amino-8-ethyl-5-oxo-2-[4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]pyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(CC)C(N)=C(C(N)=O)C(=O)C2=CN=C1NC(C=C1)=CC=C1N(CC1)CCC1N1CCCC1 VZHGRZCGUSGDLH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- IMAUTBXIILUDFN-UHFFFAOYSA-N CCNC1=NC(Cl)(C(O)=O)NC=C1 Chemical compound CCNC1=NC(Cl)(C(O)=O)NC=C1 IMAUTBXIILUDFN-UHFFFAOYSA-N 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 108030005456 Calcium/calmodulin-dependent protein kinases Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZDHJSJPFILSCTO-UHFFFAOYSA-N ClC1(NC=CC(=N1)NC1CCCC1)C(=O)F Chemical compound ClC1(NC=CC(=N1)NC1CCCC1)C(=O)F ZDHJSJPFILSCTO-UHFFFAOYSA-N 0.000 description 1
- HIXUITRHLAVPGB-UHFFFAOYSA-N ClC1(NC=CC(=N1)NCC)C(=O)F Chemical compound ClC1(NC=CC(=N1)NCC)C(=O)F HIXUITRHLAVPGB-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010072877 Intestinal fibrosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- XCUVZOBFEMEXBR-UHFFFAOYSA-N OC(=O)C1(Cl)NC=CC(NC2CCCC2)=N1 Chemical compound OC(=O)C1(Cl)NC=CC(NC2CCCC2)=N1 XCUVZOBFEMEXBR-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001054 cardiac fibroblast Anatomy 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006192 cellular response to oxidative stress Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004276 dioxalanyl group Chemical group 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- MCHMXLLGCGCRLT-UHFFFAOYSA-N dipotassium;dioxido(1,2,2-trifluoroethenoxy)borane Chemical compound [K+].[K+].[O-]B([O-])OC(F)=C(F)F MCHMXLLGCGCRLT-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- KHSBXCCTANEKRH-UHFFFAOYSA-N ethyl 4-anilino-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1NC1=CC=CC=C1 KHSBXCCTANEKRH-UHFFFAOYSA-N 0.000 description 1
- SNNHLSHDDGJVDM-UHFFFAOYSA-N ethyl 4-chloro-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1Cl SNNHLSHDDGJVDM-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- XIFJZJPMHNUGRA-UHFFFAOYSA-N n-methyl-4-nitroaniline Chemical compound CNC1=CC=C([N+]([O-])=O)C=C1 XIFJZJPMHNUGRA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- SEWKKLFOBIAYEE-UHFFFAOYSA-N o-ethyl 4-amino-6-methylpyridine-3-carbothioate Chemical class CCOC(=S)C1=CN=C(C)C=C1N SEWKKLFOBIAYEE-UHFFFAOYSA-N 0.000 description 1
- QNXIRKSJGDXWHO-UHFFFAOYSA-N o-ethyl 4-chloro-2,6-dimethylpyridine-3-carbothioate Chemical compound CCOC(=S)C1=C(C)N=C(C)C=C1Cl QNXIRKSJGDXWHO-UHFFFAOYSA-N 0.000 description 1
- AJLAUVYELPPMBI-UHFFFAOYSA-N o-ethyl 4-chloro-6-methylpyridine-3-carbothioate Chemical compound CCOC(=S)C1=CN=C(C)C=C1Cl AJLAUVYELPPMBI-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- RKCQJTTZAYJPKC-UHFFFAOYSA-N phenanthrene-9-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CC3=CC=CC=C3C2=C1 RKCQJTTZAYJPKC-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 description 1
- ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- MLTFBHXUHOGJGI-UHFFFAOYSA-N sodium;3,3,3-trifluoropropanal Chemical compound [Na].FC(F)(F)CC=O MLTFBHXUHOGJGI-UHFFFAOYSA-N 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- YVGYNZBCASAWGF-UHFFFAOYSA-N tert-butyl 4-(3-fluoro-5-methoxy-4-nitrophenyl)piperazine-1-carboxylate Chemical compound FC1=C([N+]([O-])=O)C(OC)=CC(N2CCN(CC2)C(=O)OC(C)(C)C)=C1 YVGYNZBCASAWGF-UHFFFAOYSA-N 0.000 description 1
- ZJHFTUXOGINWTB-UHFFFAOYSA-N tert-butyl 4-(3-methoxy-4-nitrophenyl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(C=2CCN(CC=2)C(=O)OC(C)(C)C)=C1 ZJHFTUXOGINWTB-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- JTZSJVLCQXZIPO-UHFFFAOYSA-N tert-butyl 4-(4-amino-3-fluoro-5-methoxyphenyl)piperazine-1-carboxylate Chemical compound FC1=C(N)C(OC)=CC(N2CCN(CC2)C(=O)OC(C)(C)C)=C1 JTZSJVLCQXZIPO-UHFFFAOYSA-N 0.000 description 1
- IWKHHOSJKSVLCT-UHFFFAOYSA-N tert-butyl 4-(4-amino-3-methoxyphenyl)piperidine-1-carboxylate Chemical compound C1=C(N)C(OC)=CC(C2CCN(CC2)C(=O)OC(C)(C)C)=C1 IWKHHOSJKSVLCT-UHFFFAOYSA-N 0.000 description 1
- POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 150000003588 threonines Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- AHDDRJBFJBDEPW-DTWKUNHWSA-N trans-2-Phenylcyclopropanecarboxylic acid Chemical compound OC(=O)[C@@H]1C[C@H]1C1=CC=CC=C1 AHDDRJBFJBDEPW-DTWKUNHWSA-N 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1050103A FR2955109B1 (fr) | 2010-01-08 | 2010-01-08 | Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique |
| PCT/FR2011/050019 WO2011086306A1 (fr) | 2010-01-08 | 2011-01-06 | Derives de 5 - oxo -5, 8- dihydropyrido [2, 3 - d] pyrimidine comme inhibiteurs de kinases camkii pour le traitement de maladies cardiovasculaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG182417A1 true SG182417A1 (en) | 2012-08-30 |
Family
ID=42244354
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012050241A SG182417A1 (en) | 2010-01-08 | 2011-01-06 | 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases |
| SG10201408059QA SG10201408059QA (en) | 2010-01-08 | 2011-01-06 | 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201408059QA SG10201408059QA (en) | 2010-01-08 | 2011-01-06 | 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8975250B2 (ru) |
| EP (1) | EP2521726B1 (ru) |
| JP (1) | JP2013516447A (ru) |
| KR (1) | KR20120112768A (ru) |
| CN (1) | CN102791710A (ru) |
| AR (1) | AR079850A1 (ru) |
| AU (1) | AU2011206475A1 (ru) |
| BR (1) | BR112012016816A2 (ru) |
| CA (1) | CA2786537A1 (ru) |
| FR (1) | FR2955109B1 (ru) |
| HK (1) | HK1177207A1 (ru) |
| MX (1) | MX2012007951A (ru) |
| RU (1) | RU2012133968A (ru) |
| SG (2) | SG182417A1 (ru) |
| TW (1) | TWI464170B (ru) |
| UY (1) | UY33167A (ru) |
| WO (1) | WO2011086306A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2954943B1 (fr) * | 2010-01-07 | 2013-03-01 | Sanofi Aventis | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique |
| US8901305B2 (en) * | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| KR102171710B1 (ko) * | 2013-01-17 | 2020-10-30 | 얀센 파마슈티카 엔.브이. | 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체 |
| DE102014201651A1 (de) * | 2014-01-30 | 2015-07-30 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Isoxazolderivate zur Verwendung bei der Behandlung und/oder Prophylaxe von Herzerkrankungen |
| AU2019232437A1 (en) | 2018-03-07 | 2020-10-08 | Bayer Aktiengesellschaft | Identification and use of ERK5 inhibitors |
| WO2020068854A1 (en) * | 2018-09-25 | 2020-04-02 | Cardurion Pharmaceuticals, Llc | Aminopyrimidine compound |
| US20220243249A1 (en) * | 2019-06-18 | 2022-08-04 | Peking University | Antagonists of camkii-delta 9 and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| MXPA06012829A (es) | 2004-05-04 | 2007-01-26 | Warner Lambert Co | Pirido[2,3-d]pirimidin-7-onas sustituidas con pirrolilo y derivados de las mismas como agentes terapeuticos. |
| FR2873118B1 (fr) * | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| CA2589808A1 (en) | 2004-11-02 | 2006-05-11 | Dainippon Sumitomo Pharma Co., Ltd. | Combination drug for treating autoimmune disease |
| KR20080045279A (ko) * | 2005-09-14 | 2008-05-22 | 얀센 파마슈티카 엔.브이. | Ｃ-ｆｍｓ 키나제 저해제로서의5-옥소-5,8-디하이드로-피리도-피리미딘 |
| WO2008055013A2 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase |
| FR2917412B1 (fr) * | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique |
| FR2917413B1 (fr) * | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
| NZ584138A (en) | 2007-08-23 | 2011-10-28 | Astrazeneca Ab | 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| WO2009042906A1 (en) | 2007-09-26 | 2009-04-02 | Regents Of The University Of Colorado | Compositions and methods for camkii inhibitors and uses thereof |
| JP2011502266A (ja) * | 2007-10-31 | 2011-01-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｆｍｓ治療に対する応答を評価するバイオマーカー |
| FR2933700B1 (fr) * | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| FR2933701A1 (fr) * | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| FR2954943B1 (fr) * | 2010-01-07 | 2013-03-01 | Sanofi Aventis | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique |
-
2010
- 2010-01-08 FR FR1050103A patent/FR2955109B1/fr not_active Expired - Fee Related
-
2011
- 2011-01-06 RU RU2012133968/04A patent/RU2012133968A/ru not_active Application Discontinuation
- 2011-01-06 BR BR112012016816A patent/BR112012016816A2/pt not_active IP Right Cessation
- 2011-01-06 AU AU2011206475A patent/AU2011206475A1/en not_active Abandoned
- 2011-01-06 SG SG2012050241A patent/SG182417A1/en unknown
- 2011-01-06 CA CA2786537A patent/CA2786537A1/fr not_active Abandoned
- 2011-01-06 WO PCT/FR2011/050019 patent/WO2011086306A1/fr active Application Filing
- 2011-01-06 KR KR1020127020682A patent/KR20120112768A/ko not_active Application Discontinuation
- 2011-01-06 SG SG10201408059QA patent/SG10201408059QA/en unknown
- 2011-01-06 EP EP11704258.0A patent/EP2521726B1/fr active Active
- 2011-01-06 JP JP2012547532A patent/JP2013516447A/ja not_active Ceased
- 2011-01-06 MX MX2012007951A patent/MX2012007951A/es active IP Right Grant
- 2011-01-06 CN CN201180012803.3A patent/CN102791710A/zh active Pending
- 2011-01-07 TW TW100100686A patent/TWI464170B/zh not_active IP Right Cessation
- 2011-01-07 UY UY0001033167A patent/UY33167A/es not_active Application Discontinuation
- 2011-01-07 AR ARP110100042A patent/AR079850A1/es unknown
-
2012
- 2012-07-09 US US13/544,209 patent/US8975250B2/en not_active Expired - Fee Related
-
2013
- 2013-04-12 HK HK13104459.1A patent/HK1177207A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2786537A1 (fr) | 2011-07-21 |
| AU2011206475A1 (en) | 2012-08-02 |
| EP2521726B1 (fr) | 2013-12-18 |
| KR20120112768A (ko) | 2012-10-11 |
| CN102791710A (zh) | 2012-11-21 |
| BR112012016816A2 (pt) | 2019-09-24 |
| JP2013516447A (ja) | 2013-05-13 |
| MX2012007951A (es) | 2012-11-21 |
| US8975250B2 (en) | 2015-03-10 |
| EP2521726A1 (fr) | 2012-11-14 |
| FR2955109A1 (fr) | 2011-07-15 |
| UY33167A (es) | 2011-08-31 |
| FR2955109B1 (fr) | 2012-09-07 |
| HK1177207A1 (en) | 2013-08-16 |
| US20120277220A1 (en) | 2012-11-01 |
| SG10201408059QA (en) | 2015-02-27 |
| WO2011086306A9 (fr) | 2011-10-27 |
| RU2012133968A (ru) | 2014-02-20 |
| TWI464170B (zh) | 2014-12-11 |
| AR079850A1 (es) | 2012-02-22 |
| WO2011086306A1 (fr) | 2011-07-21 |
| TW201139434A (en) | 2011-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2836449C (en) | Kinase inhibitors | |
| AU2009224546B2 (en) | Derivatives of tetrahydroquinoxaline urea, preparation thereof and therapeutic application thereof | |
| SG182417A1 (en) | 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases | |
| TWI393566B (zh) | 作為週期素依賴性激酶之新穎吡唑并嘧啶 | |
| ES2273047T3 (es) | Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa. | |
| EP2964646B1 (en) | Novel pyrazol derivatives | |
| EP1963315B1 (en) | Enzyme inhibitors | |
| SK287033B6 (sk) | Deriváty imidazo[1,2-a]pyridínu a pyrazolo[2,3-a]pyridínu, spôsob ich prípravy, farmaceutický prostriedok, ktorý ich obsahuje, a ich použitie | |
| NO342978B1 (no) | Pyrimidin-derivat som PI3K-inhibitor og bruk av dette | |
| KR20160145796A (ko) | BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온 | |
| EP2900653A1 (en) | Benzamide and heterobenzamide compounds | |
| CA2944610C (en) | (5,6-dihydro)pyrimido[4,5-e]indolizines | |
| SK13532001A3 (sk) | Aminopiridíny ako inhibítory sorbitoldehydrogenázy | |
| AU2004257267A1 (en) | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
| PT1278735E (pt) | 2,4-di(hetero-)arilamino(-oxi)-pirimidinas substituídas na posição 5 como agentes antineoplásicos | |
| BG107451A (bg) | Пиримидинови производни | |
| MX2012005678A (es) | Enhibidores de cinasas. | |
| AU2010210018A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| AU2014250836A1 (en) | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | |
| AU2014320149A1 (en) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | |
| CA3184990A1 (en) | Pyridazinyl amino derivatives as alk5 inhibitors | |
| US8580790B2 (en) | (Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors | |
| TW201002716A (en) | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | |
| SG172180A1 (en) | Derivatives of 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine and 6-cycloamino-2-furanyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine, preparation and therapeutic application thereof | |
| NZ720726B2 (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments |